DN T cells bearing the Ld-specific 2C transgenic TCR have been shown to be capable of inhibiting allogeneic immune responses mediated by Ld-specific 2C CD8+ T cells [20], including the rejection of skin [20], [21] and cardiac [22] allografts, and GVHD [23]. This evidence concerns the gene CD8A and graft versus host disease.